who should not take glp-1 receptor agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways The GLP-1 Agonists and Obesity:

This effect is mediated by GSH-dependent conjugation and export of anticancer drugs, diminishing their intracellular concentrations and therapeutic efficacy (5053)

Effect of cholesterol and temperature on the elastic properties of niosomal membranes

Gastro-Intestinal: Pancreatic inflammation especially in the setting of high blood lipids

Many people begin to notice changes within a few weeks, with fuller benefits building over several months of consistent, supervised use

If you first want to understand the molecular basics (GHRH receptor vs ghrelin receptor, signaling pathways, synergy), read the detailed background in GHRH vs GHRP compared